Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

Company Overview

Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing orally delivered, small-molecule therapies for endocrine conditions and other hormone-related diseases. The company’s research is centered on medicines designed to act on peptide hormone receptors, with the goal of providing alternatives to injectable therapies.

Crinetics’ lead product candidate is paltusotine, an oral, selective somatostatin receptor type 2 agonist being developed for the treatment of acromegaly, a rare disorder caused by excessive growth hormone production. The company is also developing atumelnant, formerly known as CRN04894, an oral adrenocorticotropic hormone receptor antagonist being investigated for conditions including congenital adrenal hyperplasia and Cushing’s disease.

Founded in 2008 and headquartered in San Diego, California, Crinetics conducts research and clinical development activities intended to serve patients in the United States and international markets. The company’s leadership includes founder and Chief Executive Officer Scott Struthers, Ph.D., who has guided the organization’s focus on orally administered therapies for endocrine disorders.

Key Stats

• Today's Range: $84.95 to $84.95
• 50-Day Range: $83.52 to $84.95
• 52-Week Range: $30.25 to $85.01
• Volume: N/A
• Average Volume: 2.43 million shs
• Market Capitalization: $9.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $83.44
• Consensus Rating: Hold

Crinetics Pharmaceuticals Stock Analysis - MarketRank™

Crinetics Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat, and ranked 811th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Hold

Consensus Rating

Crinetics Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 11 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Crinetics Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Crinetics Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($4.83) to ($4.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Crinetics Pharmaceuticals is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Crinetics Pharmaceuticals is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Crinetics Pharmaceuticals has a P/B Ratio of 7.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.71% of the float of Crinetics Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 2.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Crinetics Pharmaceuticals has recently increased by 3.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Crinetics Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Crinetics Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Crinetics Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.80% of the stock of Crinetics Pharmaceuticals is held by insiders.

Percentage Held by Institutions

98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRNX
• CIK: 1658247
• Web: www.crinetics.com
• Phone: (858) 450-6464
• Fax: N/A
• Employees: 210
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Crinetics Pharmaceuticals: $83.44
• High Price Target: $95.00
• Low Price Target: $67.00
• Potential Upside/Downside: -1.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$465.32 million
• Net Margins: -1,189.88%
• Pretax Margin: -1,189.45%
• Return on Equity: -44.22%
• Return on Assets: -39.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.57
• Quick Ratio: 15.53

Sales & Book Value

• Annual Sales: $7.70 million
• Price / Sales: 1,170.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.23 per share
• Price / Book: 7.56

Miscellaneous

• Outstanding Shares: 106,100,000
• Free Float: 102,063,000
• Market Cap: $9.01 billion
• Optionable: Optionable
• Beta: 0.08